Business Opportunities

Aurobindo Pharma gets USFDA approval for CVS drug

Aurobindo Pharma, a manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has received final approval for Fosinopril Sodium and Hydrocholorothizide Tablets USP 10/12.5 mg and 20/12.5 mg from the US Food and Drug Administration (USFDA). - Aurobindo sues S African govt over AIDS drug contract - Aurobindo Pharma gets TGA Australia nod for nerve drug - Aurobindo Phrama gets USFDA nod for veterinary drug - Aurobindo expands pact with Pfizer - Aurobindo expands licensing pact with Pfizer, adds 60 drugs - Aurobindo surges 6% in a falling market Fosinopril Sodium and Hydrocholorothizide Tablets USP 10/12.5 mg and 20/12.5 mg is the generic equivalent to Monopril HCT(R) Tablets 10/12.5 mg and 20/12.5 mg of Bristol Myers Squibb. Fosinopril Sodium and Hydrocholorothizide Tablets are indicated for hypertension and fall under the Cario Vascular System (CVS) theraputic segment. The product will be launched shortly. Aurobindo now has a total of 96 ANDA approvals (69 final approvals and 27 tentative approvals from USFDA).

Add your comment:

Name:
Site address:	http://
Your message:
Enter today\\\\'s date, 2 digits (spam protection):